Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: teriparatide Clear all
Completed Phase 3 Interventional Results available

Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy

NCT00577863
View directory record Official record
Conditions
Osteoporosis
Interventions
teriparatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Huntsville, Alabama • Montgomery, Alabama • Peoria, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2009 · Synced Sep 2, 2026, 2:26 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

NCT01279187
View directory record Official record
Conditions
Implant
Interventions
Teriparatide, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 2, 2026, 2:26 PM EDT
Withdrawn Not applicable Interventional

The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL

NCT00347737
View directory record Official record
Conditions
Osteoporosis
Interventions
teriparatide
Drug
Lead sponsor
Leland Graves III, MD
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison Study of PTHrP and PTH to Treat Osteoporosis

NCT00853723
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid hormone related protein(1-36), Parathyroid hormone (1-34)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

NCT00926380
View directory record Official record
Conditions
Osteoporosis
Interventions
denosumab, teriparatide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

NCT02049866
View directory record Official record
Conditions
Adult Idiopathic Generalized Osteoporosis
Interventions
Denosumab
Drug
Lead sponsor
Elizabeth Shane
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 2, 2026, 2:26 PM EDT
Terminated Not applicable Interventional Results available

Stem Cell Recruitment in Osteoporosis Therapy

NCT01656629
View directory record Official record
Conditions
Low Bone Density
Interventions
Teriparatide, Alendronate, calcium and vitamin D
Drug · Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa

NCT00759772
View directory record Official record
Conditions
Anorexia Nervosa, Osteoporosis
Interventions
Placebo, Teriparatide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur

NCT01309399
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, placebo
Drug · Other
Lead sponsor
Health Research, Inc.
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 2, 2026, 2:26 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

NCT00471237
View directory record Official record
Conditions
Osteoporosis
Interventions
Ronacaleret, Teriparatide, Alendronate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Oakland, California • Palm Desert, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

NCT00439244
View directory record Official record
Conditions
Osteoporosis
Interventions
Zoledronic acid, Placebo, Teriparatide
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 89 Years · Female only
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Sep 2, 2026, 2:26 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Combined Anabolic Therapy

NCT06558188
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Osteoporosis
Interventions
Romosozumab, Teriparatide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women

NCT01440803
View directory record Official record
Conditions
Adult Idiopathic Generalized Osteoporosis
Interventions
Teriparatide, Saline Placebo
Drug
Lead sponsor
Elizabeth Shane
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 2, 2026, 2:26 PM EDT
Terminated Phase 2 Interventional Results available

Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia

NCT00623974
View directory record Official record
Conditions
Hypocalcemia
Interventions
Teriparatide (Forteo), Calcium, Calcitriol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Results available

Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)

NCT00826228
View directory record Official record
Conditions
Osteoporosis, Bone Loss, Spinal Cord Injury
Interventions
teriparatide, weight-bearing
Drug · Other
Lead sponsor
Thomas J. Schnitzer
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Bone Properties in Hypoparathyroidism: Effects of PTH

NCT00473265
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
PTH
Drug
Lead sponsor
John P. Bilezikian
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

NCT00343252
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Back Pain, Spinal Fracture
Interventions
teriparatide, risedronate, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Montgomery, Alabama • Peoria, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Sep 2, 2026, 2:26 PM EDT
Enrolling by invitation Phase 4 Interventional

Fracture Recovery for Returning to Duty (Teriparatide STRONG)

NCT04589819
View directory record Official record
Conditions
Stress Fracture of Tibia or Fibula
Interventions
Teriparatide, Placebos
Drug
Lead sponsor
University of South Carolina
Other
Eligibility
Not listed
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

NCT00051558
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate Sodium, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
6
States / cities
Loma Linda, California • Palo Alto, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Sep 2, 2026, 2:26 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab

NCT02130973
View directory record Official record
Conditions
Osteoporosis
Interventions
Standard Clinical Practice Regimen, Experimental Cyclic Regimen
Drug
Lead sponsor
Health Research, Inc.
Other
Eligibility
45 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison Study of PF708 and Forteo in Healthy Subjects

NCT02656810
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide
Drug
Lead sponsor
Pfenex, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 4 Interventional

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

NCT00079924
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
teriparatide, aldrenodate, raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 24, 2007 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

NCT01750086
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?

NCT01166958
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Raloxifene
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years to 89 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 2, 2026, 2:26 PM EDT